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A Monte Carlo study on the feasibility of real-time in vivo source tracking during
ultrasound based HDR prostate brachytherapy treatments
Abstract

Purpose
This study aims to assess the accuracy of in-vivo source tracking during real-time trans-rectal ultrasound
(TRUS) based high dose rate (HDR) prostate brachytherapy (pBT) through Monte Carlo simulations of
multiple HDR pBT treatments with a two-dimensional (2D) diode array, the Magic Plate 900 (MP900),
embedded below the patient in a carbon-fibre couch.

Method
Monte Carlo simulations of source positions representing three separate real-time TRUS based HDR pBT
treatments were performed using the Geant4 toolkit. For each source position, an Ir-192 source was
simulated inside a voxelized patient geometry. Dose deposited from each source position to the MP900
diodes was used to perform source tracking, and the MP900 calculated position compared to known
source positions from the treatment plan. Thresholding techniques were implemented to improve source
tracking accuracy with the TRUS probe present.

Results
The average three-dimensional source position reconstruction discrepancy was 11.9 ± 2.4 mm and 1.5 ±
0.3 mm with and without the TRUS probe, respectively. Thresholding techniques improved the source
position reconstruction discrepancy in the presence of the TRUS probe to 1.8 ± 0.4 mm.

Conclusion
Inclusion of the TRUS probe inside the patient negatively affects source tracking accuracy when using the
MP900 diode array for HDR pBT verification. Modification of the source tracking algorithm using
thresholding techniques improves source tracking in the presence of the TRUS probe, achieving similar
accuracy as when the TRUS probe is not present. This study demonstrates that accurate in-vivo source
tracking during real-time TRUS based HDR pBT is feasible using the Magic Plate system.
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ABSTRACT
Purpose: This study aims to assess the accuracy of in-vivo source tracking during real-time trans-rectal
ultrasound (TRUS) based high dose rate (HDR) prostate brachytherapy (pBT) through Monte Carlo
simulations of multiple HDR pBT treatments with a two-dimensional (2D) diode array, the Magic Plate
900 (MP900), embedded below the patient in a carbon-fibre couch.
Method: Monte Carlo simulations of source positions representing three separate real-time TRUS
based HDR pBT treatments were performed using the Geant4 toolkit. For each source position, an Ir192 source was simulated inside a voxelized patient geometry. Dose deposited from each source
position to the MP900 diodes was used to perform source tracking, and the MP900 calculated position
compared to known source positions from the treatment plan. Thresholding techniques were
implemented to improve source tracking accuracy with the TRUS probe present.
Results: The average three-dimensional source position reconstruction discrepancy was 11.9 ± 2.4 mm
and 1.5 ±0.3 mm with and without the TRUS probe, respectively. Thresholding techniques improved
the source position reconstruction discrepancy in the presence of the TRUS probe to 1.8±0.4 mm.
Conclusion: Inclusion of the TRUS probe inside the patient negatively affects source tracking accuracy
when using the MP900 diode array for HDR pBT verification. Modification of the source tracking
algorithm using thresholding techniques improves source tracking in the presence of the TRUS probe,
achieving similar accuracy as when the TRUS probe is not present. This study demonstrates that
accurate in-vivo source tracking during real-time TRUS based HDR pBT is feasible using the Magic
Plate system.
Key words: in-vivo, source tracking, real-time prostate brachytherapy, Magic Plate, MP900,
Monte Carlo
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I.INTRODUCTION
High dose rate (HDR) prostate brachytherapy (pBT) treatments are widely practiced in the
radiation oncology community, most commonly in combination with external beam radiotherapy
(EBRT) in the form of a boost. There have been a number of recent studies showing improved quality
of life outcome for combined EBRT and HDR brachytherapy compared with EBRT alone [1-3].
Furthermore, there have been several studies that reported favourable results using HDR brachytherapy
as a monotherapy [4, 5].
HDR pBT treatment plans are traditionally performed with the use of a post-operative CT scan.
The major drawback of this technique is that it necessitates movement of the patient off the operating
table and out of the dorsal lithotomy position. Multiple studies have reported that movement of the
patient in this manor may increase the risk of catheter displacement in the inferior direction, relative to
the prostate, in the time between CT scanning and treatment [6, 7]. The use of transrectal ultrasound
(TRUS) for treatment planning [8] has been shown to reduce the magnitude of these shifts, as well as
improve visibility of the prostate and organs at risk (OARs) [9]. Modern brachytherapy treatment
planning systems (BTPS) are able to use the ultrasound echoes of the implanted catheters for the
definition of the catheter position within the patient, allowing for ‘real-time’ HDR pBT treatment
planning [9]. Correct identification of catheter positions on these images however can be difficult, and
there remains a need for comprehensive pre-treatment and/or in-vivo quality assurance (QA) [10-12].
Source tracking of dwell positions during HDR pBT treatments based on electronic portal
imaging devices (EPIDs) have been performed previously [13-16]. However, when used for HDR
brachytherapy source tracking, these EPID based devices are required to operate using low frame rates
due to poor signal to noise ratios, and when compounded with their inherently slow read out electronics,
loss of data for short dwell times can occur [14]. Furthermore, none of these studies have applied source
position identification to TRUS based HDR pBT, where the presence of the TRUS probe is expected to
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attenuate the signal collected by the device significantly, negatively affecting the source tracking
accuracy.
The aim of this study is to determine the feasibility of using a 2D diode array, the ‘Magic Plate
900’ (MP900), developed at the Centre for Medical Radiation Physics (CMRP), University of
Wollongong (UoW), for in-vivo source tracking during TRUS based HDR pBT. The presence of the
TRUS probe was also simulated to evaluate its effect to the source position detection. The source
tracking algorithm employed in this study utilizes the relative signal of each of the diodes in the array
to perform a distance calculation from the HDR source to each of the diodes in the array as input. The
distance from the source to each of the diodes is used in an algorithm based on a nonlinear least squares
fit method to localize the source in three dimensions. Further details of the algorithm are described in a
previous study [17]. Studies performed with a previous version of the device, the ‘Magic Plate 121’
(MP121), in homogeneous phantom media (i.e., the presence of the TRUS probe was not modelled)
have reported source localization accuracy of less than 1 mm [18-20] and timing resolution of 0.1
seconds [18]. A previous Monte Carlo study of the MP121, showed that source tracking accuracy with
the device embedded in a carbon fibre couch below a patient in the lithotomy position was achievable
to within 2 mm for CT based HDR pBT [17].

II. MATERIALS AND METHODS
To assess the feasibility of source localization using the MP900 during TRUS based HDR pBT
Monte Carlo simulations were performed using the Geant4 toolkit (v4.10.01)[21, 22]. During the
simulations, the Flexisource Ir-192 source (Elekta Brachytherapy, Veenendaal, The Netherlands) was
simulated inside a voxelized patient geometry, and the dose deposited within the sensitive volume of
each detector in the couch embedded 30x30 diode array was determined. The simulated detector dose
was then used to determine the distance of all detectors in the array to each of the simulated source
positions, and the array predicted source positions determined using an iterative process. The effect of
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the TRUS probe on source localization accuracy was ascertained by performing the simulations both
with and without a TRUS probe present in the patient volume.
II.A Ir-192 Flexisource
The geometric model of the Flexisource used in the simulations was obtained from Granero et
al.[23]. The Ir-192 core is modelled as a pure Iridium cylinder of length 3.5 mm and diameter 0.6 mm,
it has a physical density of 22.42 g/cm3. The active Ir-192 core is surrounded by a stainless-steel shell
of length 4.6 mm, 0.85 mm outer diameter and inner diameter of 0.67 mm. This results in a shell
thickness of 0.09 mm. The composition by weight of the stainless-steel shell is modelled as follows: Fe
67.92%, Cr 19%, Ni 10%, Mn 2%, Si 1% and C 0.08% and the physical density is 7.999 g/cm3. A more
detailed description and validation of the Flexisource model used in the simulations has been presented
in a previous study [17].
II.BMagic Plate 900 2-D Diode Array
The MP900 contains diodes mounted on a 0.6 mm Kapton substrate using the ‘edgeless-dropin’ technique (Figure 1), as described in a study by Petasecca et al.[24]. These diodes have an improved
angular dependence (less than 2%) compared to those used in the previous design of this system, thereby
simplifying the source reconstruction algorithm and improving source tracking accuracy. Furthermore,
the diodes have a larger sensitive volume (higher sensitivity) to allow for enhanced signal to noise ratio
at larger source-to-detector distance. The diodes are arranged in the Kapton carrier with a 7 mm pitch,
resulting in a total array size of 21 cm x 21 cm.
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Figure 1. Schematic of the MP900 and of the ‘edgeless’ diode design used source tracking simulations.
All dimensions are in millimetres, image is not to scale.

II.C Source Tracking Simulations
The MP900 was modelled in the source tracking simulations using the Geant4 toolkit
(v4.10.01)[21, 22]. The materials and geometry of the MP900 were constructed according to the
description of the device in Section II.B, embedded inside a 120 mm thick carbon fibre couch, offset 5
mm from its anterior surface.
The model of the patient anatomy in the simulations was created by converting DICOM CT
studysets from HDR pBT treatments. This was accomplished by initially converting the Hounsfield unit
(HU) to a mass density values using a CT-density curve, and then converting from mass density to a
material using a look up table [25-27]. The patient geometry in Geant4 is then created as a geometrical
phantom consisting of an array of voxels containing the materials (and their compositions) determined
from the HU [27]. The compositions and the densities of materials used in the simulations were obtained
from the AAPM TG 186 Report [28]. The voxel size was set to 3x3x3 mm in this study.
A TRUS probe was modelled inside the rectum of the voxelized patient geometries by utilizing
a parallel geometry [29] to prevent overlapping volumes in the simulation, e.g. patient rectum and
TRUS probe. These overlapping volumes cause errors in the tracking geometry of Geant4 simulations,
leading to erroneous results. The TRUS probe was constructed based on the Endocavity Biplane
Transducer Type 8848 produced by BK Medical. The model of the probe consisted of a 110x15x3 mm
bar of brass (70% Copper, 30% Zinc, effective atomic number of 29.5), embedded inside a cylindrical
Silicon casing (length 200 mm, diameter 22 mm). It should be noted that this model may not be
representative of the true construction of the model 8848 probe, as details of the internal construction
of the probe were unable to be obtained from the manufacturer. Therefore, a model was used that was
intended to match the internal construction of the probe to the best of our knowledge and mimicked the
construction of a probe analogue previously used in experiments by our institution [30]. Due to the
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presence of the high atomic number materials inside the TRUS probe, it was expected that the TRUS
probe would attenuate the signal collected by the MP900 significantly, negatively affecting the source
tracking accuracy. Nevertheless, it’s important to note that the TRUS probe must remain in the rectum
during patient irradiation in order to not modify the patient’s anatomy acquired for treatment planning
[11].
Three complete HDR pBT treatments were simulated, consisting of three unique voxelized
patient geometries. The source position locations from the treatment plans were re-created in the
simulation geometry by using the three-dimensional source position locations obtained from the
DICOM RTPlan files in the BTPS. As the patient geometry is also re-created in the simulations directly
from the DICOM files, the position of the dwell locations relative to the patient anatomy in the
simulations matches the BTPS. The characteristics of the three HDR pBT plans included in the study
are outlined in Table I. The Flexisource model used in the simulations is described in Section II.A. The
total energy deposited in the sensitive volume of each diode in the array was tallied during each
simulation, which consisted of a total of 109 primary photons. The total energy deposited in the sensitive
region of each diode was then divided by the mass of the sensitive volume to calculate the dose
deposited. The source positions were then determined using the average diode dose as input into an
source tracking algorithm [17, 18, 31]
Table I – Characteristics of the three HDR pBT plans considered in the study.

Patient 1
Patient 2
Patient 3

Number of catheters
19
22
18

Number of source positions
154
165
153

Finally, the MP900 determined source positions were compared to known source positions
input into the simulations, which were obtained from the Oncentra Prostate (v4.2.3 Elekta
Brachytherapy, Veenendaal, The Netherlands) BTPS. Source positions obtained from the BTPS
coordinate system were converted to that of the MP900 coordinate system, as the position of the MP900
relative to the patient geometry is known, fixed distance (the MP900 is rigidly embedded into the carbon
6

fibre couch below the patient) within the simulation geometry. The simulations were repeated with the
TRUS probe replaced by tissue equivalent material in the patient geometry to examine the effect of the
TRUS probe on the source tracking accuracy.
To determine if the same accuracy of source tracking can be achieved both with and without
the TRUS probe present, a thresholding technique was applied to the source tracking algorithm. Firstly,
using the data from the simulations with the TRUS probe present, the maximum dose deposited in any
diode was found for each source position. Secondly, for each source position in the three patient plans
a threshold was applied, ranging from 50% - 90% of the maximum dose deposited in the array in 10%
increments. Any diode with dose deposited below this threshold is ignored in the algorithm, and the
optimal threshold level found that gave the best results as input into the source tracking algorithm when
all source positions from the three treatment plans were considered.
The average and maximum differences between MP900 predicted and actual source positions
obtained with the TRUS probe, without the TRUS probe, and TRUS probe corrected (i.e. applying the
optimal threshold), were computed and compared across all three patient volumes. Results without the
TRUS probe and TRUS probe corrected were also compared by means of a Wilcoxian matched pair
test. A p-value of <0.05 was considered significant. The test was performed using the R software (v3.5.1,
The R Foundation for Statistical Computing, Vienna, Austria).

III. RESULTS
The average three-dimensional (3D) error vector of source tracking in the presence of the TRUS
probe is shown in Table II for each direction within the three patient volumes, including: the patient
left-right direction (X), superior-inferior direction (Y), and anterior-posterior direction (Z). The average
3D error vector for all source positions in the three treatment plans was found to be 11.9 ± 2.4 mm (k =
1). Figure 2.a) presents the distance calculation between each diode in the MP900 array from a source
position in patient 1’s plan with the TRUS probe present. The colour scale represents the MP900
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calculated distance (in mm) from each diode to the source. The effect of the TRUS probe can clearly be
seen in the figure, resulting in an incorrect distance calculation for the diodes shadowed by the probe.

a)

b)

c)
Figure 2.a) Distance calculation (mm) between the source and each diode in the MP900 from a source
position in Patient 1 plan, affected by the presence of the TRUS probe.2.b) Distance calculation, without
the TRUS probe present, 2.c) Distance calculation with 70% threshold applied, and diodes with red
colours not included in the reconstruction algorithm.
The simulations were then repeated without the TRUS probe present in the patient geometry
examine the effect of the TRUS probe on the source tracking accuracy. Figure 2.b) presents the distance
calculation between each diode in the MP900 array from a source position in patient 1’s plan without
the TRUS probe present. The average 3D error vector for all source positions in the three treatment
plans without the TRUS probe was 1.5 ± 0.3 mm (k = 1).
Table II – Average difference between MP900 predicted and actual source positions in mm with, without and corrected for a TRUS probe with standard deviation (k=1) in the patient’s
rectum.
8

Error
Direction

With
TRUS
Probe

Patient 1
Without
TRUS
Probe

TRUS
Probe
Corrected

With
TRUS
Probe

Patient 2
Without
TRUS
Probe

TRUS
Probe
Corrected

With TRUS
Probe

X
Y
Z
3D

6.1 ± 1.2
6.0 ± 1.4
8.1 ± 2.2
11.8 ± 2.4

0.4 ± 0.4
0.4 ± 0.2
1.3 ± 0.2
1.4 ± 0.3

0.6 ± 0.5
0.6 ± 0.5
1.6 ± 0.4
1.8 ± 0.6

6.6 ± 1.4
6.3 ± 1.1
7.8 ± 2.7
12.0 ± 2.5

0.4 ± 0.4
0.4 ± 0.2
1.3 ± 0.2
1.4 ± 0.3

0.7 ± 0.6
0.6 ± 0.4
1.4 ± 0.4
1.7 ± 0.6

5.8 ± 1.3
6.0 ± 1.5
8.4 ± 2.1
11.8 ± 2.3

Patient 3
Without
TRUS
Probe

TRUS
Probe
Corrected

0.5 ± 0.4
0.5 ± 0.3
1.5 ± 0.5
1.7 ± 0.4

0.7 ± 0.8
0.7 ± 0.7
1.5 ± 0.8
1.8 ± 0.7

A thresholding technique was applied to the verification algorithm with the TRUS probe
present. Figure 2.c) presents the distance calculation between each diode in the MP900 array from a
source position in patient 1’s plan with the TRUS probe present and a 70% threshold applied. As can
be seen from the figure, the threshold is able to eliminate the diodes shadowed by the TRUS probe as
input into the verification algorithm. The effect of the application of different threshold levels in the
source tracking algorithm is shown in Figure 3. The optimal threshold level, averaged over all source
positions in the three treatment plans was found to be 70%. By disregarding the signal of all diodes
below 70% of the maximum signal of any diode in the array, an average source tracking accuracy of
1.8±0.4 mm can be achieved in the clinically relevant condition of the presence of the TRUS probe
inside the rectum.
As can be seen in Table II, the variation in the 3D source tracking accuracy across the three
patient volumes is less than 0.5 mm. This result highlights the excellent reproducibility of the MP900
system and associated source tracking algorithm, regardless of variations in patient related tissue
inhomogeneities. The maximum difference between MP900 predicted and actual source position was
15.4 mm, 2.2 mm, and 3.0 mm, with the TRUS probe, without the TRUS probe, and TRUS probe
corrected (70% threshold), respectively across all three patient volumes. The difference between the
latter two datasets was found to be statistically significant, with p < 0.001.
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Figure 3. Effect of threshold level in the source tracking algorithm. The 3D error vector in the presence
of the TRUS probe is shown in green (k=1). The 3D error vector without the TRUS probe is shown in
red (k=1). The 3D error vector with different threshold levels applied is shown in blue, pink, and orange,
for patients 1, 2 and 3, respectively (k=1).
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Figure 4. Average 3D source tracking error in each catheter considered in the study for patient 1, ± 1
standard deviation. Red columns show the average error without the TRUS probe. Blue columns show
the average error with the TRUS probe present and a 70% threshold level applied.
The results were broken down further to show the average 3D error achieved per catheter
(Figure 4) for patient 1 only, both without the TRUS probe and with the 70% threshold level applied.
The catheter numbers increase in the posterior to anterior direction; therefore, the increasing catheter
number represents an increasing distance between the source and the MP900 array. Typical average
distances between the source positions in each catheter and the MP900 array ranged from 95 mm to 145
mm. A trend is observed showing an increased 3D error with increasing average distance between the
source and the array.
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Figure 5. 3D source tracking error in the form of a box-whisker plot for catheter 2 (C2) and catheter 8
(C8). TRUS probe present and TRUS probe corrected results are presented for each catheter.
Figure 5 presents a box-whisker plot focusing on catheter 2 and catheter 8 from the patient 1
plan. Catheter 2 is an example of a catheter which is not shadowed by the TRUS probe as viewed from
the MP900 array. Catheter 8 is an example where the TRUS probe shadows the primary radiation from
the Ir-192 source from most detectors in the MP900 array.

IV. DISCUSSION
The presence of the TRUS probe was found to significantly affect the accuracy of source
tracking in all three dimensions. Source tracking accuracy without the TRUS probe using the MP900
was found to be similar, but improved by approximately 0.5 mm, to that found previously using the
MP121 device [17]. The major discrepancy remains in the z direction (patient anterior-posterior
direction). The discrepancy in the z direction has been shown previously to be in particular due to the
non-water equivalence of patient tissue related inhomogeneities between the source and the diode array.
This was shown by repeating the simulations with each voxel in the geometry assigned a density of
12

water, resulting in a significant improvement in source tracking accuracy [17]. This effect is highlighted
even more so in Figure 4, where an increased 3D error vector is observed with increasing distance
between source position and the array, due to the increasing likelihood of the material composition
between the source and the array being different to that of water.
The effect of the TRUS probe on source tracking accuracy can be overcome using a
thresholding technique. An optimal threshold level of 70% of the maximum diode signal was found for
all source positions in three complete HDR pBT treatment plans. With this threshold of 70%,
approximately 60% of the detectors in the MP900 are not being used for source position verification
for the reported example case (patient 1). However, the total number of detectors used in the verification
algorithm under these conditions is on average equal to 315. This is approximately 2.5 times the total
number of detectors in the previous version of the device (MP121 array) and justifies the need for the
MP900 for this purpose. As shown in Figure 3, the 70% threshold level was found to be optimal for all
three patient geometries, and there was remarkably little variation in source tracking accuracy between
the three patient geometries. The optimal threshold level may depend more on the TRUS probe design
and composition, rather than the patient geometry. The effect of the TRUS probe type and design on the
optimal threshold level will be investigated further in future experimental studies with the MP900.
Source position detection is in principle impossible, even applying a threshold technique, if the
source is so close to the probe that its primary radiation oriented towards the array is shielded by the
probe. Defining a the distance between the centre of the TRUS probe and the array, b the distance
between the upper surface of the TRUS probe and the source, h the length of the array (i.e. 100 mm for
the MP121 and 210 mm for the MP900) and d the diameter of the probe (i.e. 22 mm for the Endocavity
Biplane Transducer Type 8848 produced by BK Medical) (Figure 6.a)), the following equation
𝑎𝑎+𝑏𝑏+𝑑𝑑/2
ℎ

=

𝑏𝑏+𝑑𝑑/2
𝑑𝑑

is valid when the “shadow” of the source matches the lateral edges of the array. In

Figure 6.b), this equation was used to simulate b depending on both a and the diode array dimensions.
According to the plot, the use of MP900 allows the reconstruction of the source position even if it is
over the TRUS probe and close to it, covering all the possible clinical situations. This wouldn’t be
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possible with the MP121, in particular at increasing distances between TRUS probe and detector array.
A typical clinical example is shown in Figure 6.c), with a needle 10.4 mm over the TRUS surface.

a)

b)
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c)

Figure 6.a) Schematic of the setup with the source, TRUS probe and Magic Plate array. a is the distance
between the centre of the TRUS probe and the array; b is the distance between the external surface of
the TRUS probe and the source; h is the length of the array; d is the diameter of the probe. Image is not
to scale; b) Minimum source-probe distance b necessary to avoid the complete shielding of the primary
radiation of the source that would be detected by the array, plotted at changing array-probe distance a;
c) TRUS image of the prostate after needle implantation. The closest needle is 10.4 mm over the TRUS
probe.
Figure 5 shows on patient 1 an example of a catheter (catheter 2) which is not shadowed by the
TRUS probe as viewed from the MP900 array and of a catheter (catheter 8) where the TRUS probe
shadows the primary radiation from the Ir-192 source from most detectors in the MP900 array. Even
for catheter 8, which is positioned directly anterior to the TRUS probe, the modified source tracking
algorithm results in a similar source tracking accuracy to when no probe is present. However, when
compared to catheter 2, the modified source tracking algorithm applied to catheter 8 results in larger
discrepancies relative to when there is no probe present. As shown in table 2, there is a higher standard
deviation of the 3D error results in the TRUS probe corrected group (0.6 mm) compared to the results
without the TRUS probe (0.3 mm). This is due to the larger uncertainty in correcting for the presence
of the TRUS probe for catheters that are located directly above the probe where less detectors in the
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MP900 array can be used for input into the verification algorithm. In general, 3D errors resulted
significantly higher (p < 0.001) in the TRUS probe corrected group than in the group without TRUS
probe. Nevertheless, an average source tracking accuracy lower than 2 mm (i.e., 1.8±0.4 mm) can be
achieved in the clinically relevant condition of the presence of the TRUS probe inside the rectum, after
application of the TRUS probe correction method.
The results from this study indicate that the MP900 will have sufficient sensitivity to detect
errors of approximately 2 mm in the delivery of TRUS based HDR pBT treatments. Such errors may
include incorrect catheter connection, incorrect source strength, or incorrect reference length entered
into the BTPS. Errors of this magnitude may also be due to uncertainties in reconstruction of catheters
on ultrasound images, for example Rylander et al.[10] have shown that errors in catheter reconstruction
on TRUS images relative to MRI may be up to 9.6 mm. Furthermore, possible needle displacements
occurring during the treatment planning phase (i.e., post-imaging intra-fraction modifications), which
might result in changes in the dosimetry of the prostate and OARs [11, 32], could also be detected by
the use of MP900.
There still remains, however, a number of significant challenges that must be overcome before
translating these source tracking simulation studies to routine in-vivo source tracking in clinical practice.
One example is the poor signal to noise ratio experienced by the detector system at such large source to
detector distances, when the detector system is placed beneath the patient during HDR pBT. This poor
signal to noise ratio necessitates the use of longer integration times in the detector system and may
therefore preclude the system from performing real-time source tracking analysis. This issue has been
discussed in previous publications on the use of EPID devices for source tracking [13-16]. The Magic
Plate system, however, is capable of operating with variable integration times between 14 – 9900 μs,
with a stable sampling frequency between 0.1 – 10 kHz. Previous publications on the application of the
Magic Plate system to HDR brachytherapy source tracking have demonstrated that real-time analysis is
possible [18, 19]. Optimisation of detector integration times and sampling frequencies when performing
source tracking in-vivo will be a focus of future publications.
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Another challenge that is still to be overcome is the registration of the MP900 to the BTPS
coordinate system. The accuracy of source tracking can only be as good as the registration between
these coordinate systems, and previous publications have incorporated stereoscopic imaging [13, 14],
or electromagnetic tracking [33] in attempts to perform this registration. However, this issue remains
one of the most significant challenges for accurate localisation of the source position and will also be a
focus of future publications on experimental results using the MP900 system in combination with gel
phantoms.

V. CONCLUSION
This study presents a novel methodology for performing source tracking during real-time TRUS
based HDR pBT. Inclusion of the TRUS probe inside the patient was shown to negatively affect source
tracking accuracy. However, modification of the source tracking algorithm using thresholding
techniques was shown to improve source tracking in the presence of the TRUS probe. An optimal
threshold level of 70% of the maximum diode signal at each source position was determined for all
source positions in three complete HDR pBT treatment plans, with minor variation observed across the
three patient volumes. Using this thresholding technique, similar accuracy can be achieved as to when
the TRUS probe is not present inside the patient volume, highlighting the robustness of the proposed
solution.
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